Not only is Sanofi Pasteur at the forefront of conquering newly targeted diseases, but the company is also leading the way in expanding immunization across all age groups, including adolescents and the elderly. This leadership has translated into outstanding success in the industry.
Sanofi Pasteur is interested in partners who will share in the pursuit of innovation and the company’s drive for excellence while becoming a part of its market success story. “We welcome the opportunity to evaluate technologies related to the development and production of human vaccines, both prophylactic and therapeutic, including vaccines for chronic infectious diseases,” said Roman Chicz, global head of external research and development.
A volunteer is vaccinated during clinical testing of Sanofi Pasteur’s dengue vaccine. Sanofi Pasteur is improving global human health by discovering, developing, manufacturing and supplying vaccines for the prevention and treatment of infectious diseases.
Sanofi Pasteur’s new vaccine to prevent dengue is now licensed in fourteen countries. Dengue is a threat to about half of the world’s population and a health priority in many countries of Latin America and Asia where epidemics occur. Currently, there is no specific treatment available for dengue fever. Sanofi Pasteur’s goal is to make dengue the next vaccine-preventable disease and to support the World Health Organization’s effort to reduce dengue mortality by 50% and morbidity by 25% by 2020.
Sanofi Pasteur has a strong commitment to establishing research and development partnerships with major universities, research institutes, government bodies, biotechnology companies and contract research organizations. The company’s collaborations cover virtually all aspects of vaccine development, including early-stage research.
Examples of current partnerships and technology investments include a protective monoclonal antibody against respiratory syncytial virus (RSV) infection for infants; vaccine candidates against Zika virus, RSV, herpes simplex virus, S. pneumoniae, and broadly protective influenza; pediatric combination vaccines; large-scale cell-culture based virus production; adjuvants and immunomodulators; conjugate vaccine production; and vaccine delivery systems.
A company partnering with Sanofi Pasteur interacts with a multidisciplinary team that has years of experience in working to ensure that partnerships are executed successfully and nurtured for the mutual benefit of all parties. This approach utilizes the value-added Sanofi Pasteur alliance management capability, which focuses on the relationship by facilitating open communication, trust, understanding and clear expectations across the project life span.
Combined with the technical competency of the alliance, this balance provides a well-rounded environment in which novel technologies can flourish. Currently, 100% of its preclinical portfolio and ~65% of its clinical portfolio has a partnering component.
Sanofi Pasteur welcomes information about new partnership opportunities. Each opportunity is care-fully evaluated and reviewed by its dedicated team.
Sanofi Pasteur is interested in potential partnering opportunities in the field of active and passive human immunization for infectious diseases, as well as technologies supporting product development and industrial performance, including in the following areas:
Vaccines, monoclonal antibodies and supporting technologies for prevention and treatment of infectious diseases
• Novel antigens and methods for antigen discovery and characterization
• Vaccine vectors suitable for nasal or oral use
• New ways to administer vaccines
• Carrier proteins and protein-polysaccharide conjugation methods or alternative technologies
Agents to enhance vaccine immune responses
• Adjuvants and immunomodulators
• Vaccine vectors and delivery systems intended to enhance or modify immune responses
• Biological and immunological studies to further characterize adjuvants and immunomodulators
Characterization and assay of immune responses and disease markers
• Animal models of human diseases
• Biological markers for evaluating the efficacy of prophylactic or therapeutic interventions
• In vitro models of human tissues, including the immune system
• Epidemiological studies relevant to the use of vaccines and immunotherapeutics
• 3D tissue models
Tools for improving vaccine and monoclonal antibody research, development and production
• Development and application of new technologies in the areas of genomics and proteomics
• Prokaryotic or eukaryotic cell lines for antigen production
• Fermentor and bioreactor technology
• Disposable systems
• Online testing
• Downstream processing, purification and aseptic filling processes
• Process automation
• Preservatives and stabilizers
• Bioinformatics techniques for modeling, data handling and analysis
• Anti-counterfeiting technology
Roman Chicz, Head,
External Research and Development
Jean-Louis Grunwald, Vice President,
Tel: +65 64 31 22 10